Shopping Cart
Remove All
Your shopping cart is currently empty
ATN-658 is a humanized monoclonal antibody target the Domain 3 region of the urokinase-type plasminogen activator receptor, inhibition of cellular migration and invasion by disrupting the functional interaction between the receptor and various integrin signaling partners within designated preclinical oncology models.

| Description | ATN-658 is a humanized monoclonal antibody target the Domain 3 region of the urokinase-type plasminogen activator receptor, inhibition of cellular migration and invasion by disrupting the functional interaction between the receptor and various integrin signaling partners within designated preclinical oncology models. |
| In vitro | In PC-3 prostate cancer cell assays, ATN-658 caused a significant dose-dependent decrease in cell motility without affecting doubling time [1]. |
| In vivo | In intratibial PC-3 xenograft models, systemic administration of ATN-658 resulted in a significant decrease in tumor volume and skeletal lesions [1]. |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | PLAUR/uPAR/CD87 |
| Isotype | IgG1 |
| Storage | store at low temperature | -20°C for 2 years, 4°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.